Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic…


Previous articleBetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
Next articlePT441 – The American Psychedelic Practitioners Association and the Mission to Integrate Psychedelics into U.S. Healthcare